Champions Oncology (CSBR) Cost of Revenue (2017 - 2026)

Champions Oncology has reported Cost of Revenue for 10 years, with the latest figure at $6.8 million in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 6.34% year-over-year to $6.8 million in Q2 2026; TTM through Apr 2026 was $30.9 million, a 8.85% increase from a year earlier, with the FY2026 full-year figure at $30.9 million, up 8.84% from the prior year.
• Cost of Revenue was $6.8 million for Q2 2026 at Champions Oncology, down from $8.8 million in the prior quarter.
• The five-year high for Cost of Revenue was $8.8 million in Q1 2026, with the low at $6.2 million in Q2 2022.
• Average Cost of Revenue over 5 years is $7.3 million, with a median of $7.3 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue surged 38.57% in 2022, then declined 15.7% in 2025.
• Over 5 years, Cost of Revenue stood at $7.4 million in 2022, then retreated by 11.08% to $6.6 million in 2023, then rose by 12.24% to $7.4 million in 2024, then retreated by 2.23% to $7.3 million in 2025, then dropped by 6.22% to $6.8 million in 2026.
• The last three Cost of Revenue figures came in at $6.8 million (Q2 2026), $8.8 million (Q1 2026), and $7.3 million (Q4 2025), per Business Quant data.